Announcements Archive
NCI CIRB Stakeholders,
As of Wednesday, May 22, 2024, Outcome Letters for Initial Reviews, Amendments, and Continuing Reviews will now include the Adult Risk category. Stakeholders will also continue to find the Adult Risk category in the Applications.
This change was made in response to requests from CIRB stakeholders. The NCI CIRB hopes this change will help to streamline work processes for all stakeholders.
Hello,
The NCI CIRB is announcing its annual ‘open call’ for new board members. Our goal is to populate the boards with members who represent diverse backgrounds and experiences, and who can review NCIs research with competence and confidence. This year, we are recruiting medical oncologists, pharmacists, statisticians, and patient representatives. We will be accepting applications through July 19th, 2024.
CIRB Participants,
CIRB Stakeholders,
As of January 2, 2024, each study closure will require the completed and approved Early Study Closure Confirmation form. The Early Study Closure Confirmation form will be required for all studies, even those where no participants have been enrolled.
CIRB STAKEHOLDERS,
The CIRB’s Annual Signatory Institution Worksheet and Quickguide have been revised to reflect changes to the following questions:
CIRB Stakeholders,
To provide a more updated and integrated experience for all stakeholders who reach out to the NCI CIRB Helpdesk, we are transitioning to a new helpdesk management system (Zendesk).
CIRB Stakeholders,
The NCI CIRB is announcing its annual ‘open call’ for new board members. Our goal is to populate the boards with members who represent diverse backgrounds and experiences, and who can review NCIs research with competence and confidence. This year we are recruiting for medical oncologists and statisticians. We will be accepting applications through July 21st.
Hello,
The NCI CIRB is announcing its annual ‘open call’ for new board members. Our goal is to populate the boards with members who represent diverse backgrounds and experiences, and who can review NCIs research with competence and confidence. This year we are recruiting for medical oncologists and statisticians. We will be accepting applications through July 21st.
Unanticipated Problem and/or Serious or Continuing Noncompliance Application
The NCI CIRB has created an application for the submission of potential unanticipated problems and/or serious or continuing noncompliance for trial-wide review by the boards.
CIRB Stakeholders,
The NCI CIRB has updated its guidance regarding the requirements for a witness. Witnesses will no longer be required by NCI. The inclusion of a witness in the remote consent process is now dictated by local institutional policy and must follow FDA and OHRP requirements.
Thank you
CIRB Operation Office